Abiopharma

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Enhanced Group Announces $50 Million Strategic Financing Led by Enhanced Co-Founder and Chairman Christian Angermayer; Management Expects Company Fully Funded Through Profitability

Coda Octopus Group Reports Fiscal Second Quarter 2026 Financial Results

Alexandre Ruberti, Seasoned Beverage Executive and Zevia Board Member, Appointed Chief Executive Officer

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

Surge Copper Announces Results of Berg Pre-Feasibility Study with After-Tax NPV8% of C$4.6 billion and 24% IRR

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

OTC Markets Group Names Thomas Fasano Head of Broker-Dealer Sales

Lightbridge to Participate in Upcoming Investor and Nuclear Industry Events